DI IOIA, MARIA
 Distribuzione geografica
Continente #
NA - Nord America 1.483
EU - Europa 1.156
AS - Asia 631
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
AF - Africa 1
Totale 3.283
Nazione #
US - Stati Uniti d'America 1.482
CN - Cina 305
IE - Irlanda 225
IT - Italia 191
UA - Ucraina 179
TR - Turchia 149
GB - Regno Unito 146
SE - Svezia 138
SG - Singapore 110
FR - Francia 86
DE - Germania 82
IN - India 49
FI - Finlandia 40
RU - Federazione Russa 30
CZ - Repubblica Ceca 17
BE - Belgio 12
EU - Europa 7
VN - Vietnam 6
AU - Australia 5
IR - Iran 4
DK - Danimarca 2
GR - Grecia 2
KR - Corea 2
PL - Polonia 2
AM - Armenia 1
CA - Canada 1
EG - Egitto 1
HR - Croazia 1
IL - Israele 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
PH - Filippine 1
PK - Pakistan 1
RO - Romania 1
TW - Taiwan 1
Totale 3.283
Città #
Chandler 288
Jacksonville 251
Dublin 222
Southend 116
Princeton 94
Singapore 94
Nanjing 85
Ashburn 81
Ann Arbor 76
Izmir 73
Beijing 69
Chieti 67
Dearborn 62
Wilmington 40
Cambridge 39
New York 34
Altamura 32
Santa Clara 30
Nanchang 29
Boardman 21
Woodbridge 18
Los Angeles 16
Washington 16
Grevenbroich 15
Brno 14
Kunming 14
Shenyang 13
Brussels 12
Jiaxing 12
Guangzhou 11
Hebei 11
Norwalk 11
Tianjin 11
Hangzhou 9
San Mateo 8
Changsha 7
Houston 7
Monmouth Junction 7
Dong Ket 6
Falls Church 6
Jinan 6
Lanzhou 6
London 6
Munich 5
Pescara 5
Roseto Degli Abruzzi 5
Changchun 4
Edinburgh 4
Hanover 4
Helsinki 4
San Vito Chietino 4
Seattle 4
Teramo 4
Zhengzhou 4
Ardabil 3
Augusta 3
La Spezia 3
Milan 3
Mumbai 3
Ningbo 3
Olomouc 3
Taizhou 3
Tatura 3
Torino 3
Benevento 2
Campodipietra 2
Copenhagen 2
Fairfield 2
Kraków 2
L'aquila 2
Leawood 2
Padova 2
Pianella 2
Redmond 2
Redwood City 2
Tappahannock 2
Verona 2
Andover 1
Anzio 1
Arlington 1
Atlanta 1
Auburn Hills 1
Bangalore 1
Boston 1
Brisbane 1
Cairo 1
Campobasso 1
Candiolo 1
Centrale 1
Chengdu 1
Düsseldorf 1
Frankfurt am Main 1
Genova 1
Hefei 1
Hobart 1
Hyderabad 1
Jian 1
Lanciano 1
Manchester 1
Manila 1
Totale 2.171
Nome #
An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis 140
Enhanced release of acid sphingomyelinase-enriched exosomes generates a lipidomics signature in CSF of Multiple Sclerosis patients 139
Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid 118
Cleavage of cystatin C is not associated with multiple sclerosis 104
UNRAVELING THE MOLECULAR REPERTOIRE OF TEARS AS A SOURCE OF BIOMARKERS: BEYOND OCULAR DISEASES 103
Integration of metabolomics and proteomics in multiple sclerosis: from biomarkers discovery to personalized medicine 103
A lipidomic investigation for the caracterisation of CSF lipid profile in patients with multiple sclerosis 98
Metabolomic Signature in Sera of Multiple Sclerosis Patients during Pregnancy 97
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 92
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 90
Metabolomics analysis of cerebrospinal fluid reveals a distintive biochemical alteration associated with multiple sclerosis. 90
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 88
TLC-MALDI-Imaging approach for lipidomics studies in cerebrospinal fluid reveals low levels of sphingomyelin in multiple sclerosis patients 85
Increasing age at disability milestones among MS patients in the MSBase Registry 83
Data of safety in a single-center alemtuzumab treated population 79
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 77
Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center 77
Acetylcholine in multiple sclerosis: possible involvement in the modulation of the immune response and in oligodendrocyte recruitment. 76
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 73
Nail loss after teriflunomide treatment: a new potential adverse event 72
Development of methods for lipid extraction from CSF and application of mass spectometry techniques for the characterization of the lipid profile and neurosteroids levels in MS patients 71
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 70
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 69
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 69
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 69
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 69
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 68
Mass spectrometry based metabonomics of the cerebrospinalfluid highlights a correlation between polar lipids and carnitines levels in multiple sclerosis patients. 67
Natalizumab-associated PML-IRIS: the Chieti experience. 66
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 65
JCV-Ab serostatus in MS patients treated with Natalizumab 65
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 65
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 63
Proteomic investigations on differential post-translational modification of transthyretin in multiple sclerosis. 63
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 63
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group 61
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 59
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 57
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 57
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis 50
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients 48
Lipidomics analysis reveals low levels of phosphatidylcholines and sphingomyelins in cerebrospinal fluido f multiple sclerosis patients. 46
Contribution of metabolomics to multiple sclerosis diagnosis, prognosis and treatment 46
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 44
Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis 43
Totale 3.397
Categoria #
all - tutte 11.723
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.723


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020436 0 0 9 5 44 51 81 59 25 79 68 15
2020/2021283 46 3 59 3 5 52 5 0 41 25 30 14
2021/2022232 4 4 9 42 9 13 10 20 16 9 24 72
2022/2023757 61 109 43 74 93 133 34 54 104 15 24 13
2023/2024394 17 18 33 6 30 181 48 5 1 8 2 45
2024/2025232 50 103 79 0 0 0 0 0 0 0 0 0
Totale 3.397